TICKERNERD
Menu
IBRXIBRXHealthcare · Biotechnology

IBRX Stock Forecast: ImmunityBio, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$8.31
−3.82% on the day

The 4 Wall Street analysts covering ImmunityBio, Inc. hold a median 12-month price target of $15 — +74.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 21 Oct 2026 — in the upper half.

Market cap
$9.2B
Ticker Nerd rank
58/ 100
Median analyst target
$15
Analysts covering
4
Revenue$51.2M+93.9% y/y
Operating income−$61.7M
Net income−$230.4M
Free cash flow−$70.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.9%
1M
−10.5%
YTD
+319.7%
1Y
+252.1%
From 52W high
−28.1%
From 52W low
+319.7%
$2
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IBRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ImmunityBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
58/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Value
91
Accruals
90
Revisions
60
Quality
48
Growth
45
Volatility
32
Size
16
Issuance
7

Momentum (93): The shares have been drifting up relative to others.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IBRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IBRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Jan 26Apr 26Jul 26Oct 26IBRXHigh $16Median $15Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $12Median $15High $16

The green dot is the last close — the median target sits +74.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 Oct 2026HC Wainwright & Co.ReiteratesBuy$15
15 Oct 2026JefferiesMaintainsBuy$12 → $14
2 June 2026HC Wainwright & Co.ReiteratesBuy$15
2 June 2026HC Wainwright & Co.ReiteratesBuy—
21 May 2026BTIGReiteratesBuy—
20 May 2026HC Wainwright & Co.ReiteratesBuy—
5 May 2026D. Boral CapitalMaintainsBuy—
21 Apr 2026D. Boral CapitalMaintainsBuy—
8 Apr 2026D. Boral CapitalMaintainsBuy—
26 Mar 2026D. Boral CapitalMaintainsBuy—
23 Mar 2026D. Boral CapitalMaintainsBuy—
17 Mar 2026D. Boral CapitalMaintainsBuy—
12 Mar 2026BTIGAssumesBuy$13
9 Mar 2026D. Boral CapitalMaintainsBuy—
4 Mar 2026Piper SandlerReiteratesOverweight—
23 Feb 2026D. Boral CapitalMaintainsBuy—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
19 Feb 2026D. Boral CapitalMaintainsBuy—
17 Feb 2026D. Boral CapitalMaintainsBuy—
26 Jan 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IBRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

IBRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, ImmunityBio, Inc. returned +252.1% against +15.6% for the S&P 500, dividends included.

IBRX vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Jan 26Apr 26Jul 26Oct 26IBRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IBRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

ImmunityBio, Inc. (IBRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−21.3×

Cheaper than 97% of US stocks

Price / sales
51.3×

Cheaper than 5% of US stocks

Price / book
−8.1×

Cheaper than 97% of US stocks

EV / EBITDA
−42.6×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
93.9%

Higher than 92% of US stocks

Earnings growth (YoY)
93.9%

Higher than 83% of US stocks

Gross margin
99.4%

Higher than 99% of US stocks

Operating margin
−120.4%

Higher than 13% of US stocks

Net margin
99.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
70.3%

Higher than 95% of US stocks

Return on assets
−30.5%

Higher than 14% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ImmunityBio, Inc. (IBRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ImmunityBio, Inc. has a market value of $9.2B and an enterprise value of $10.0B.

  • Revenue in the twelve months to 30 June 2026: $165.8M. The latest quarter grew 93.9% year on year.

  • Net income over the same four quarters: −$992.4M, a −598.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.97.

  • Free cash flow in the twelve months to 30 June 2026: −$288.5M.

  • Shares outstanding: 1.1B.

  • Trailing P/E: −21.3×; forward P/E: −50.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ImmunityBio, Inc. employs 684 people — $242K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

IBRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IBRXImmunityBio, Inc.$9.2B58
CAICaris Life Sciences, Inc.$9.1B48
PTGXProtagonist Therapeutics, Inc.$8.8B98
KYMRKymera Therapeutics, Inc.$9.4B82
CYTKCytokinetics, Inc.$8.7B48
KRYSKrystal Biotech, Inc.$9.5B75
SYRESpyre Therapeutics, Inc.$8.6B44

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ImmunityBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IBRX news & analysis

ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

Business Wire · 21 Oct 2026positive

ImmunityBio announced completion of the database lock for Cohort A of QUILT-2.005, a randomized, controlled, registrational trial comparing bladder-delivered ANKTIVA plus BCG with BCG alone in BCG-naïve patients with non-muscle invasive bladder cancer.

Why it matters — The update marks a trial milestone for the chemotherapy-free combination being evaluated in this patient group.

ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment

Benzinga · 19 Oct 2026positive

A study published in the Journal of Urology reported promising long-term results for ImmunityBio’s immunotherapy treatment, ANKTIVA, in bladder cancer.

Why it matters — The reported long-term results provide an update on clinical evidence for ImmunityBio’s bladder cancer treatment.

ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

Business Wire · 16 Oct 2026positive

ImmunityBio reported publication of long-term Phase 2/3 QUILT-3.032 data evaluating ANKTIVA plus BCG in patients with BCG-unresponsive NMIBC with CIS, with or without papillary disease. The headline reports 84% cystectomy avoidance at three years and complete responses beyond 53 months.

Why it matters — The reported long-term study outcomes provide an update on the clinical data for ImmunityBio’s ANKTIVA-plus-BCG regimen in this bladder cancer population.

FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer

Zacks Investment Research · 15 Oct 2026positive

The FDA expanded the label for ImmunityBio’s Anktiva in combination with BCG to cover all patients with BCG-unresponsive non-muscle-invasive bladder cancer.

Why it matters — The expanded approval broadens Anktiva’s eligible patient population and commercial opportunity.

ImmunityBio Stock Climbs Thursday: What's Going On?

Benzinga · 15 Oct 2026positive

ImmunityBio shares traded higher Thursday after the FDA expanded ANKTIVA’s approved indication to include BCG-unresponsive non-muscle-invasive bladder cancer with papillary-only tumors.

Why it matters — The expanded indication is relevant to IBRX watchers because it broadens the types of bladder cancer covered by ANKTIVA’s approval.

FAQ

Frequently asked questions about IBRX stock

What is the IBRX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering ImmunityBio, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IBRX stock a buy right now?

Of the 4 analysts covering ImmunityBio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ImmunityBio, Inc. 58 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IBRX?

As at 21 Oct 2026, ImmunityBio, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will IBRX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +74.5% from the last close, and Ticker Nerd's factor model ranks ImmunityBio, Inc. 58 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IBRX stock forecast for 2030?

No analyst covering ImmunityBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $16 over the next 12 months.

How has IBRX stock performed over the past year?

ImmunityBio, Inc. returned +252.1% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ImmunityBio, Inc. do?

ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems.

What is the latest news on IBRX?

The most recent item we track (Business Wire, 21 Oct 2026): "ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer". ImmunityBio announced completion of the database lock for Cohort A of QUILT-2.005, a randomized, controlled, registrational trial comparing bladder-delivered ANKTIVA plus BCG with BCG alone in BCG-naïve patients with non-muscle invasive bladder cancer.

Company

About ImmunityBio, Inc.

ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company also works on additional biologic platforms, including cytokine fusion proteins, DNA and vaccine vectors, NK-cell therapies, and other immunomodulators for cancer and infectious diseases. ImmunityBio’s products and research programs are aimed at addressing unmet needs in oncology and infectious disease treatment through immune-based approaches. Headquartered in San Diego, California, ImmunityBio operates as a commercial-stage company with a focus on bringing biologic therapies from development into clinical use.

CEO Mr. Richard Gerald Adcock · 684 employees · United States · https://immunitybio.com